On March 25, 2026, Hengrui Pharma (600276.SH; 01276.HK) announced robust financial results for the full year 2025, fueled by its dual strategy of innovation and globalization.
More info..

The fifth Asia Summit on Global Health (ASGH) and the 16th Hong Kong International Medical and Healthcare Fair (Medical Fair), both organised by the Hong Kong Trade Development Council (HKTDC), have drawn to a successful close. As flagship events of International Healthcare Week (IHW), both ASGH and the Medical Fair brought global healthcare stakeholders together, including government officials and organisations, research pioneers, investors, and business leaders.
More info..

Novaliq GmbH, a pharmaceutical company focusing on first- and best-in-class ocular therapeutics, and Jiangsu Hengrui Medicine Co., Ltd. (SSE: 600276), a fully integrated biopharmaceutical company based in China, announced the closing of an exclusive license agreement to develop, manufacture and commercialize the innovative, water-free drugs NOV03 and CyclASol(R) for the treatment of dry eye disease in the People's Republic of China (mainland China, Hong Kong, Macau and Taiwan).
More info..